博雅生物(300294) - 2022 Q4 - 年度财报

Financial Performance - The company’s operating revenue for 2022 was ¥2,758,701,315.10, representing a 4.08% increase compared to ¥2,650,528,421.87 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥432,197,553.97, a 25.45% increase from ¥344,528,999.52 in 2021[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥392,124,538.69, up 33.61% from ¥293,492,852.21 in 2021[17]. - The company's cash flow from operating activities decreased by 55.67% to ¥596,437,198.85 in 2022, down from ¥1,345,377,085.21 in 2021[17]. - The total assets at the end of 2022 were ¥8,033,175,408.45, a 5.40% increase from ¥7,621,775,902.48 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were ¥7,185,634,486.84, reflecting a 5.22% increase from ¥6,829,074,243.57 at the end of 2021[17]. - The company achieved total operating revenue of ¥2,758,701,315.10, a year-on-year increase of 4.08%[45]. - The operating profit reached ¥532,180,673.01, reflecting a growth of 20.12% compared to the previous year[45]. - The blood products business generated operating revenue of ¥1,342,217,158.74, up 8.96% from ¥1,231,862,874.38 in 2021[46]. - The diabetes business saw a decline in operating revenue to ¥178,390,600.88, down 25.01% due to the impact of centralized procurement policies[46]. - The biopharmaceutical business reported operating revenue of ¥438,116,868.80, a decrease of 14.25% influenced by product exits from medical insurance[47]. - The pharmaceutical distribution business (Fuda Pharmaceutical) achieved operating revenue of ¥814,214,548.78, an increase of 22.69% driven by increased sales of immunoglobulin products[47]. Dividend Distribution - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 504,248,738 shares[4]. - The company plans to distribute a cash dividend of 1.5 yuan per 10 shares, totaling 75,637,310.70 yuan (including tax) based on a share base of 504,248,738 shares[162]. - The total cash dividend amount for the year is 100,849,747.60 yuan (including tax), which accounts for 100% of the total profit distribution[164]. - The company reported a distributable profit of 2,086,809,493.36 yuan for the year[164]. - The company has not proposed any stock bonus distribution for the reporting period[165]. Market and Product Development - The company reported a total of 9 product varieties in the blood products sector, with a significant market demand exceeding the current supply[26]. - The domestic market for blood products reached ¥43 billion in 2021, with a year-on-year growth of 11.17%[28]. - The estimated demand for raw plasma in China has exceeded 16,000 tons per year, while the actual collection was approximately 10,181 tons in 2022, indicating a supply shortfall[28]. - The company focuses on blood products, including albumin, immunoglobulin, and coagulation factors, and is one of the leading domestic producers in this sector, offering 9 product varieties in 23 specifications[33]. - The company aims to become a world-class blood product enterprise while stabilizing its non-blood product business, emphasizing the importance of blood products in its overall strategy[33]. - The company has increased R&D investment to enhance its product pipeline, being one of the few in the industry with a complete range of three types of products[29]. - The company has optimized its product structure with the recent launch of PCC and factor VIII, improving its core product yield above the industry average[29]. - The company has achieved a balance between production and sales for its core products, enhancing its market penetration and coverage through academic system development[29]. - The company aims to expand its market presence and enhance product competitiveness through new strategies and product development[35]. - The company launched new products, including the production approval of coagulation factor VIII, enhancing its product portfolio[50]. Research and Development - The company has a strong R&D capability, having undertaken over 20 government projects and holding more than 200 patents, with ongoing projects aimed at expanding its blood product offerings[58]. - The number of R&D personnel increased to 220 in 2022, a growth of 2.33% compared to 215 in 2021[78]. - R&D expenditure amounted to ¥77,174,985.45 in 2022, representing 2.80% of operating revenue, down from 3.39% in 2021[78]. - The company is currently conducting clinical research on several products, including the von Willebrand factor and intravenous immunoglobulin, with significant development expenditures reported[78]. - The company has committed to returning all temporarily used idle funds to the dedicated fundraising account by the end of the specified period[100]. Operational Challenges and Strategies - The company experienced a significant decline in cash flow from operating activities, which may impact future investment and operational strategies[17]. - The company faces risks in new product development due to long cycles and high costs; it will conduct comprehensive market research and strengthen project management to ensure timely product launches[117]. - The company is adapting to increasing regulatory pressures in the pharmaceutical industry by optimizing production capacity and enhancing product pipelines to counter potential price declines[119]. - The company is committed to enhancing its operational management capabilities at plasma stations, focusing on cost control and quality management to increase plasma collection volume[109]. - The company plans to implement a series of operational optimization measures to achieve steady growth in revenue and net profit in 2023[112]. Environmental Compliance - The company has successfully passed environmental protection inspections and complies with national emission standards, ensuring no pollution to surrounding environments[175]. - The company’s COD discharge is 83.518 mg/L, well below the industry standard of 220 mg/L, with a total discharge of 4.227 tons[178]. - The company reported a total nitrogen level of 5.898 mg/L at the North Corner facility, which is below the regulatory limit of 40 mg/L[179]. - The company achieved a liquid waste discharge of 3.8905 tons, adhering to the wastewater discharge standards[179]. - The company has implemented online monitoring for wastewater parameters to ensure compliance with environmental standards[179]. Corporate Governance - The company has established a fair, transparent, and effective performance evaluation and incentive mechanism for senior management, aiming to attract and retain outstanding talent[129]. - The company maintains complete independence in business, personnel, assets, organization, and finance from its controlling shareholders, ensuring independent operations[131][132][133][134][135]. - The company has a dedicated board secretary responsible for information disclosure, ensuring timely and accurate communication with shareholders[129]. - The company has set up three specialized committees under the board of directors to enhance operational efficiency[129]. - The company held its annual general meeting with a participation ratio of 42.97% on April 12, 2022, and a temporary shareholders' meeting with a participation ratio of 46.31% on January 28, 2022[137].